Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 22.88% | Argus Research | → $110 | Initiates Coverage On | → Buy |
| 03/28/2023 | -65.37% | BTIG | $20 → $31 | Maintains | Buy |
| 12/12/2022 | 61.97% | TD Cowen | $130 → $145 | Maintains | Outperform |
| 06/28/2022 | — | UBS | Downgrades | Neutral → Sell | |
| 06/07/2022 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 05/31/2022 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 03/16/2022 | — | Deutsche Bank | Upgrades | Hold → Buy | |
| 01/25/2022 | — | Liberum | Downgrades | Hold → Sell | |
| 12/20/2021 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 01/15/2021 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 01/17/2020 | 391.51% | B of A Securities | $420 → $440 | Reiterates | → Neutral |
| 01/03/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 11/18/2019 | — | UBS | Downgrades | Buy → Neutral | |
| 11/18/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 09/17/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 09/13/2019 | 346.83% | B of A Securities | $355 → $400 | Reiterates | → Neutral |
| 08/30/2019 | — | Jefferies | Downgrades | Hold → Underperform | |
| 06/20/2019 | — | Deutsche Bank | Downgrades | Buy → Hold | |
| 06/11/2019 | — | Barclays | Upgrades | Underweight → Equal-Weight | |
| 04/29/2019 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
| 01/29/2019 | — | Exane BNP Paribas | Initiates Coverage On | → Outperform | |
| 12/14/2018 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 12/11/2018 | 218.36% | Jefferies | → $285 | Assumes | → Hold |
| 11/19/2018 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 10/08/2018 | — | B of A Securities | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2023 年 2 月 10 日 | 22.88% | 阿格斯研究 | → 110 美元 | 启动覆盖范围开启 | → 购买 |
| 03/28/2023 | -65.37% | BTIG | 20 美元 → 31 美元 | 维护 | 购买 |
| 2022 年 12 月 12 日 | 61.97% | TD Cowen | 130 美元 → 145 美元 | 维护 | 跑赢大盘 |
| 06/28/2022 | — | 瑞银（UBS） | 降级 | 中性 → 卖出 | |
| 2022 年 7 月 6 日 | — | 摩根大通 | 升级 | 中性 → 超重 | |
| 05/31/2022 | — | 古根海姆 | 升级 | 中性 → 买入 | |
| 2022 年 3 月 16 日 | — | 德意志银行 | 升级 | 持有 → 买入 | |
| 01/25/2022 | — | liberum | 降级 | 持有 → 卖出 | |
| 2021 年 12 月 20 日 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 2021 年 1 月 15 日 | — | 德意志银行 | 启动覆盖范围开启 | → 购买 | |
| 2020 年 1 月 17 日 | 391.51% | B of A 类证券 | 420 美元 → 440 美元 | 重申 | → 中立 |
| 01/03/2020 | — | 古根海姆 | 降级 | 买入 → 中性 | |
| 11/18/2019 | — | 瑞银（UBS） | 降级 | 买入 → 中性 | |
| 11/18/2019 | — | 巴克莱 | 升级 | 重量相等 → 超重 | |
| 09/17/2019 | — | 花旗集团 | 升级 | 中性 → 买入 | |
| 09/13/2019 | 346.83% | B of A 类证券 | 355 美元 → 400 美元 | 重申 | → 中立 |
| 08/30/2019 | — | 杰富瑞 | 降级 | 持有 → 表现不佳 | |
| 06/20/2019 | — | 德意志银行 | 降级 | 买入 → 持有 | |
| 2019 年 11 月 6 日 | — | 巴克莱 | 升级 | 体重不足 → 重量相等 | |
| 2019 年 4 月 29 日 | — | 瑞士信贷 | 升级 | 中性 → 跑赢大盘 | |
| 2019 年 1 月 29 日 | — | Exane BNP Paribas | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2018 年 12 月 14 日 | — | 摩根士丹利 | 启动覆盖范围开启 | → 重量相等 | |
| 12/11/2018 | 218.36% | 杰富瑞 | → 285 美元 | 假设 | → 按住 |
| 11/19/2018 | — | 摩根大通 | 升级 | 中性 → 超重 | |
| 10/08/2018 | — | B of A 类证券 | 降级 | 买入 → 中性 |
What is the target price for Novo Nordisk (NVO)?
诺和诺德（NVO）的目标价格是多少？
The latest price target for Novo Nordisk (NYSE: NVO) was reported by Argus Research on October 2, 2023. The analyst firm set a price target for $110.00 expecting NVO to rise to within 12 months (a possible 22.88% upside). 3 analyst firms have reported ratings in the last year.
阿格斯研究中心于2023年10月2日公布了诺和诺德（纽约证券交易所代码：NVO）的最新目标股价。该分析公司将目标股价定为110.00美元，预计NVO将在12个月内上涨至22.88％（可能上涨22.88％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Novo Nordisk (NVO)?
分析师对诺和诺德（NVO）的最新评级是多少？
The latest analyst rating for Novo Nordisk (NYSE: NVO) was provided by Argus Research, and Novo Nordisk initiated their buy rating.
诺和诺德（纽约证券交易所代码：NVO）的最新分析师评级由阿格斯研究公司提供，诺和诺德启动了买入评级。
When is the next analyst rating going to be posted or updated for Novo Nordisk (NVO)?
诺和诺德（NVO）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与诺和诺德的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Novo Nordisk的最后一次评级是在2023年10月2日提交的，因此你应该预计下一个评级将在2024年10月2日左右公布。
Is the Analyst Rating Novo Nordisk (NVO) correct?
分析师对诺和诺德（NVO）的评级是否正确？
While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a initiated with a price target of $0.00 to $110.00. The current price Novo Nordisk (NVO) is trading at is $89.52, which is within the analyst's predicted range.
虽然评级是主观的，并且会发生变化，但最新的诺和诺德（NVO）评级最初的目标价为0.00美元至110.00美元。诺和诺德（NVO）的当前交易价格为89.52美元，在分析师的预测区间内。